relative risk for moderate to severe diastolic dysfunction versus mild dysfunction and normal function is 3.8 for CV1 and 3.9 for CV2. Mild diastolic dysfunction in this subset carries a similar prognosis as in the full study (7% vs. 6%), whereas the normal group has a nonsignificantly better prognosis (0% vs. 4%).
Patent Foramen Ovale and Stroke Risk: The Devil Is in the Detail
The risk of stroke due to a patent foramen ovale (PFO) is real. Case reports document venous thrombi slipping through a foramen ovale to the left atrium and causing a stroke (1). The absolute risk for ischemic strokes in the presence of a PFO is unknown. The report of Di Tullio et al. (2) in a recent issue of the Journal may not shed more light on this question, because some "minor" details could end up seriously biasing their results.
As the investigators point out in their discussion, the prevalence of a PFO in the general population is close to one-quarter (3). The prevalence of a PFO in the current study is 15%. The most likely reason for this low PFO prevalence is underdiagnosis of interatrial shunts by transthoracic echocardiography (4) . Otherwise, the researchers have to argue for a lower PFO prevalence in citizens from northern Manhattan compared to other cities of the U.S. Missing 4 of 10 PFOs would lower the hazard ratio (HR) for stroke in the PFO group compared to the non-PFO group, because these nondiagnosed shunts may increase the risk for stroke in the latter group. The results of the Cox regression models as presented would underestimate the actual hazard. In addition to the problem of underdiagnosis, a question arises regarding the patients studied. The mean age of patients participating in this project was 68 to 69 years. The association of a PFO and stroke has been demonstrated for patients Ͻ55 years (5) and is probably weaker in the elderly with competing conventional cardiovascular risk factors as hypertension, diabetes, and dyslipidemia.
Last but not least, Di Tullio et al. (2) should provide not only the HR for a stroke in the setting of a PFO, but also the corresponding HRs for other cardiovascular risk factors they corrected for. Normal 33% (n ϭ 98) 31% (n ϭ 56) 0% 0% Mild dysfunction 22% (n ϭ 65) 29% (n ϭ 53) 7% (n ϭ 4) 11% (n ϭ 6) Moderate dysfunction 37% (n ϭ 109) 31% (n ϭ 55) 15% (n ϭ 8) 22% (n ϭ 12) Severe dysfunction 7% (n ϭ 21) 9% (n ϭ 17) 12% (n ϭ 2) 18% (n ϭ 3)
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